Non-Hallucinogenic Psychedelic Treatment For Anxiety And Depression In Pre-Clinical Models: Enveric Biosciences' Breakthrough Research
Psychedelics biotech company Enveric Biosciences (NASDAQ: ENVB) has presented research highlighting the company's lead compound, EB-003 at the 7th Neuropsychiatric Drug Summit. The conference is being held at the Hilton Boston Back Bay in Boston, Massachusetts on Sept. 24-26, 2024. EB-003 is a neuropathogenic and non-hallucinogenic N, N-Dimethyltryptamine (DMT) analog drug candidate that showed beneficial outcomes in preclinical models of anxiety and depression. The move follows the company's July announcement of positive pre-clinical results of its EB-003 drug candidate to be delivered via oral administration. The results indicated that oral administration of EB-003 provides significant brain exposure in rodent models at potential therapeutic doses.
